PACIFIC

A Phase 3, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage 3) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222682

Enrollment

Unknown

Registered

2014-12-08

Start date

2014-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

investigational material(s) Generic name etc : MEDI4736 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Documented evidence of NSCLC (locally advanced, unresectable, Stage 3III) -Patients must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy. -World Health Organisation (WHO) Performance Status of 0 to 1. -Estimated life expectancy of more than 12 weeks.

Exclusion criteria

Exclusion criteria: -Prior exposure to any anti-PD-1 or anti-PD-L1 antibody. -Active or prior autoimmune disease or history of immunodeficiency. -Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV. -Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris. -Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy. -Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026